Search Results - "Visseren‐Grul, Carla"

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY by Nishio, Makoto, Seto, Takashi, Reck, Martin, Garon, Edward B., Chiu, Chao‐Hua, Yoh, Kiyotaka, Imamura, Fumio, Park, Keunchil, Shih, Jin‐Yuan, Visseren‐Grul, Carla, Frimodt‐Moller, Bente, Zimmermann, Annamaria, Homma, Gosuke, Enatsu, Sotaro, Nakagawa, Kazuhiko

“…In the global phase III RELAY study, ramucirumab plus erlotinib (RAM + ERL) demonstrated superior progression‐free survival (PFS) to placebo plus erlotinib…”
Get full text

Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer by Middleton, Gary, Gridelli, Cesare, De Marinis, Filippo, Pujol, Jean-Louis, Reck, Martin, Ramlau, Rodryg, Parente, Barbara, Pieters, Thierry, Visseren-Grul, Carla M, San Antonio, Bélen, John, William J, Zimmermann, Annamaria Hayden, Chouaki, Nadia, Paz-Ares, Luis

“…To assess the effect of long-term pemetrexed maintenance therapy on patients' renal function. In the PARAMOUNT phase III trial (NCT 00789373), pemetrexed was…”
Get full text

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer by PAZ-ARES, Luis G, DE MARINIS, Filippo, CORRAL, Jesús, MELEMED, Symantha, JOHN, William, CHOUAKI, Nadia, ZIMMERMANN, Annamaria H, VISSEREN-GRUL, Carla, GRIDELLI, Cesare, DEDIU, Mircea, THOMAS, Michael, PUJOL, Jean-Louis, BIDOLI, Paolo, MOLINIER, Olivier, TARINI PRASAD SAHOO, LAACK, Eckart, RECK, Martin

“…In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62;…”
Get full text

Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study by Veltkamp, Stephan A, Jansen, Robert S, Callies, Sophie, Pluim, Dick, Visseren-Grul, Carla M, Rosing, Hilde, Kloeker-Rhoades, Susanne, Andre, Valerie A M, Beijnen, Jos H, Slapak, Christopher A, Schellens, Jan H M

“…Purpose: To determine the toxicity, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral gemcitabine…”
Get full text

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial by Paz-Ares, Luis, Dr, de Marinis, Filippo, MD, Dediu, Mircea, MD, Thomas, Michael, Prof, Pujol, Jean-Louis, Prof, Bidoli, Paolo, MD, Molinier, Olivier, MD, Sahoo, Tarini Prasad, MD, Laack, Eckart, Prof, Reck, Martin, MD, Corral, Jesús, MD, Melemed, Symantha, PhD, John, William, MD, Chouaki, Nadia, MD, Zimmermann, Annamaria H, MS, Visseren-Grul, Carla, MD, Gridelli, Cesare, MD

“…Summary Background Patients with advanced non-squamous non-small-cell lung cancer (NSCLC) benefit from pemetrexed maintenance therapy after induction therapy…”
Get full text

Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non–Small-Cell Lung Cancer by SCAGLIOTTI, Giorgio V, PASTORINO, Ugo, TORRI, Valter, VANSTEENKISTE, Johan F, SPAGGIARI, Lorenzo, FACCIOLO, Francesco, ORLOWSKI, Tadeusz M, MAIORINO, Luigi, HETZEL, Martin, LESCHINGER, Monika, VISSEREN-GRUL, Carla

“…This study aimed to determine whether three preoperative cycles of gemcitabine plus cisplatin followed by radical surgery provides a reduction in the risk of…”
Get full text

Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review) by ZINNER, RALPH, GRUL, CARLA VISSEREN, SPIGEL, DAVID R, OBASAJU, COLEMAN

“…Because poor performance status (PS) is an independent prognostic factor in non-small cell lung cancer (NSCLC), PS scores are widely used by oncologists to…”
Get full text

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer by RADEMAKER-LAKHAI, Jeany M, BEEREPOOT, Laurens V, VAN HAL, Gertjan, BEIJNEN, Jos H, SCHELLENS, Jan H. M, VOEST, Emile E, MEHRA, Niven, RADEMA, Sandra A, VAN MAANEN, Rianne, VERMAAT, Joost S, WITTEVEEN, Els O, VISSEREN-GRUL, Carla M, MUSIB, Luna, ENAS, Nathan

“…Purpose: Enzastaurin targets the protein kinase C and phosphatidylinositol 3-kinase/AKT pathways to reduce tumor angiogenesis and cell proliferation and to…”
Get full text

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review by Garon, Edward B, Visseren-Grul, Carla, Rizzo, Maria Teresa, Puri, Tarun, Chenji, Suresh, Reck, Martin

“…In the REVEL trial, ramucirumab plus docetaxel demonstrated significant improvements in overall survival (OS), progression-free survival (PFS), and overall…”
Get full text

Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations by Winfree, Katherine B, Molife, Cliff, Peterson, Patrick M, Chen, Yongmei, Visseren-Grul, Carla M, Leusch, Mark S, Beyrer, Julie, Dimou, Anastasios

“…To estimate real-world (rw) outcomes for first-line therapy in patients with advanced EGF receptor ( )-mutated non-small-cell lung cancer (NSCLC), focusing on…”
Get full text

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer by SOCINSKI, Mark A, SMIT, Egbert F, JASSEM, Jacek, DEDIU, Mircea, SHENGYAN HONG, VISSEREN-GRUL, Carla, HANAUSKE, Axel-Rainer, OBASAJU, Coleman K, GUBA, Susan C, THATCHER, Nick, LORIGAN, Paul, KONDURI, Kartik, RECK, Martin, SZCZESNA, Aleksandra, BLAKELY, Johnetta, SERWATOWSKI, Piotr, KARASEVA, Nina A, CIULEANU, Tudor

“…Following a phase II trial in which pemetrexed-platinum demonstrated similar activity to that of historical etoposide-platinum controls, a phase III study was…”
Get full text

Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program by Santoro, Armando, O'Brien, Mary E, Stahel, Rolf A, Nackaerts, Kristiaan, Baas, Paul, Karthaus, Meinolf, Eberhardt, Wilfried, Paz-Ares, Luis, Sundstrom, Stein, Liu, Yushan, Ripoche, Veronique, Blatter, Johannes, Visseren-Grul, Carla M, Manegold, Christian

“…Previously published results from a randomized phase III study of pemetrexed plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated…”
Get more information

Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial by Nicolson, Marianne C, Fennell, Dean A, Ferry, David, O'Byrne, Kenneth, Shah, Riyaz, Potter, Vanessa, Skailes, Geraldine, Upadhyay, Sunil, Taylor, Paul, André, Valerie, Nguyen, Tuan S, Myrand, Scott P, Visseren-Grul, Carla, Das, Mayukh, Kerr, Keith M

“…In retrospective analyses of patients with nonsquamous non-small-cell lung cancer treated with pemetrexed, low thymidylate synthase (TS) expression is…”
Get more information

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study by Belani, Chandra P, Prof, Brodowicz, Thomas, MD, Ciuleanu, Tudor E, MD, Krzakowski, Maciej, Prof, Yang, Sung Hyun, MD, Franke, Fábio, MD, Cucevic, Branka, MD, Madhavan, Jayaprakash, MD, Santoro, Armando, MD, Ramlau, Rodryg, MD, Liepa, Astra M, PharmD, Visseren-Grul, Carla, MD, Peterson, Patrick, PhD, John, William J, MD, Zielinski, Christoph C, Prof

“…Summary Background Pemetrexed maintenance therapy significantly improved overall survival and progression-free survival compared with placebo, and had a good…”
Get full text

RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants by Nishino, Kazumi, Shih, Jin-Yuan, Nakagawa, Kazuhiko, Reck, Martin, Garon, Edward B., Carlsen, Michelle, Matsui, Tomoko, Visseren-Grul, Carla, Nadal, Ernest

“…EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo (PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for…”
Get full text

Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer by Gridelli, Cesare, de Marinis, Filippo, Pujol, Jean-Louis, Reck, Martin, Ramlau, Rodryg, Parente, Barbara, Pieters, Thierry, Middleton, Gary, Corral, Jesus, Winfree, Katherine, Melemed, Symantha, Zimmermann, Anna, John, William, Beyrer, Julie, Chouaki, Nadia, Visseren-Grul, Carla, Paz-Ares, Luis G

“…In a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demonstrated significant benefit in advanced non-small-cell lung cancer…”
Get more information

Pemetrexed Therapy in Elderly Patients With Good Performance Status: Analysis of Two Phase III Trials of Patients With Nonsquamous Non–Small-Cell Lung Cancer by Gridelli, Cesare, Brodowicz, Thomas, Langer, Corey J, Peterson, Patrick, Islam, Mominul, Guba, Susan C, Moore, Patti, Visseren-Grul, Carla M, Scagliotti, Giorgio

“…Micro-Abstract The efficacy and safety of pemetrexed treatment was evaluated in elderly patients with nonsquamous advanced non–small-cell lung cancer and a…”
Get full text

Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study by Fennell, Dean A, Myrand, Scott P, Nguyen, Tuan S, Ferry, David, Kerr, Keith M, Maxwell, Perry, Moore, Stephen D, Visseren-Grul, Carla, Das, Mayukh, Nicolson, Marianne C

“…We report exploratory gene-expression profiling data from a single-arm Phase-II-study in patients with non-squamous (ns)NSCLC treated with pemetrexed and…”
Get full text

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC by Nishio, Makoto, Nishio, Kazuto, Reck, Martin, Garon, Edward B., Imamura, Fumio, Kawaguchi, Tomoya, Yamaguchi, Hiroyuki, Ikeda, Satoshi, Hirano, Katsuya, Visseren-Grul, Carla, Ceccarelli, Matteo, Wijayawardana, Sameera R., Zimmermann, Annamaria, Matsui, Tomoko, Enatsu, Sotaro, Nakagawa, Kazuhiko

“…Ramucirumab (RAM) plus erlotinib was found to have superior progression-free survival (PFS) versus placebo plus erlotinib in untreated EGFR-mutated metastatic…”
Get full text

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset by Nishio, Kazuto, Seto, Takashi, Nishio, Makoto, Reck, Martin, Garon, Edward B., Sakai, Kazuko, Goto, Koichi, Kato, Terufumi, Nakanishi, Yoichi, Takahashi, Toshiaki, Yamamoto, Nobuyuki, Kiura, Katsuyuki, Ohe, Yuichiro, Tamura, Tomohide, Visseren-Grul, Carla, Frimodt-Moller, Bente, Hozak, Rebecca R., Wijayawardana, Sameera R., Zimmermann, Annamaria, Homma, Gosuke, Enatsu, Sotaro, Nakagawa, Kazuhiko

“…The phase 3 RELAY global study (NCT02411448) revealed significant improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM + ERL)…”
Get full text